We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


RainDance Forms Hematologic Oncology Consortium

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RainDance Forms Hematologic Oncology Consortium"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

RainDance Technologies, Inc. has announced the formation of the RainDance HemOnc Consortium, composed of a select group of hematologic clinical research experts drawn from prominent comprehensive cancer centers in the U.S. and Europe.

Members of the consortium will present first data on a new ThunderBolts Myeloid Panel using next-generation sequencing (NGS) during the American Society of Hematology (ASH) Annual Meeting in San Francisco on December 6-9, 2014.

The HemOnc Consortium partnered with RainDance to address the unmet need for a highly accurate, rapid, simple, and low-cost NGS panel to study myeloid disorders, especially in genes that are difficult to routinely detect with existing methods.

The ThunderBolts Myeloid Panel, the first RainDance product co-developed with the HemOnc Consortium, is a targeted NGS assay which enables cancer researchers to analyze important genes implicated in the causation, prognosis and recurrence of myeloid disorders.

The HemOnc Consortium will also work with RainDance to develop a proprietary digital PCR (dPCR) portfolio of cell-free mutation assays to study and monitor the status of important genes in hematologic oncology progression and relapse.

“The MLL (Munich Leukemia Laboratory) has worked with RainDance for several years to develop cutting-edge targeted sequencing panels for myeloid malignancies,” said Torsten Haferlach, M.D., Member of the HemOnc Consortium and CEO at MLL. “The new ThunderBolts Myeloid Panel provides us with the most up-to-date and comprehensive assay for detecting myeloid gene mutations, and the ability to follow up sequencing by sensitively tracking mutations in plasma using RainDance’s digital PCR system.”

The ThunderBolts Myeloid Panel covers approximately 50 genes including full exons and/or targeted regions of challenging genes such as CEBPA, NOTCH1, NPM1, and IDH1&2. The panel provides 100 percent coverage at 100x sequencing depth and more than 95 percent coverage at 1000x depth with greater than 95 percent uniformity, equivalent to sensitivity at or below five percent mutation frequencies.

Starting input DNA requirements are as low as 10ng. The workflow is also simple with integrated sequencing and indexing adapters to eliminate library preparation for total turnaround time of less than two days (sample to sequencing data).

“We feel the ThunderBolts Myeloid Panel is an exciting tool that interrogates the spectrum of relevant genetic variants and may improve NGS workflow and library quality,” added Eric Padron, M.D., Member of the HemOnc Consortium and Section Head of Genomics and Personalized Medicine in the Malignant Hematology Department at Moffitt Cancer Center.

“Our goal with the ThunderBolts Myeloid Panel is to provide researchers and the industry with a single rapid, highly accurate and low-cost sequencing assay in an area of high unmet need,” said Roopom Banerjee, RainDance Technologies’ President and CEO. “This product pairs well with our RainDrop Digital PCR System, which enables researchers to study and follow important driver mutations in circulating cell-free fluids.”

2014 American Society of Hematology Annual Meeting and Exposition
RainDance is showcasing its products for liquid biopsy applications at the American Society of Hematology (ASH) Annual Meeting in San Francisco at booth #2645.